STOCK TITAN

Gracell Biotechnologies Inc - GRCL STOCK NEWS

Welcome to our dedicated news page for Gracell Biotechnologies (Ticker: GRCL), a resource for investors and traders seeking the latest updates and insights on Gracell Biotechnologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gracell Biotechnologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gracell Biotechnologies's position in the market.

Rhea-AI Summary
Gracell Biotechnologies Inc. (NASDAQ: GRCL) wins BioTech Breakthrough’s Overall Immunology Solution of the Year award for FasTCAR-T GC012F, a CAR-T therapy candidate demonstrating positive data in multiple myeloma and B-cell non-Hodgkin’s lymphoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.02%
Tags
none
-
Rhea-AI Summary
Gracell Biotechnologies Inc. will present updated results from its clinical investigator-initiated trial of GC012F, a FasTCAR-enabled autologous BCMA and CD19 dual-targeted CAR-T cell therapy, for the treatment of newly diagnosed multiple myeloma (NDMM). The Phase 1 trial is evaluating the safety and efficacy of GC012F in transplant-eligible, high-risk NDMM patients. The updated results, including longer-term follow-up and data from additional patients, will be presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.65%
Tags
conferences
-
Rhea-AI Summary
Gracell Biotechnologies Inc. announced its participation in four upcoming investor conferences in November. The conferences include Stifel 2023 Healthcare Conference, Jefferies London Healthcare Conference, Piper Sandler 35th Annual Healthcare Conference, and 6th Annual Evercore ISI HealthCONx Conference. Dr. Kevin Xie, the Chief Financial Officer, will be presenting at these conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.65%
Tags
conferences
Rhea-AI Summary
Gracell Biotechnologies Inc. announces preclinical data on their SMART CART™ technology for solid tumors. The technology demonstrates resistance to immunosuppressive tumor microenvironment and maintains long-term proliferation and cytotoxicity. Gracell is launching an investigator-initiated trial targeting Claudin 18.2 positive tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.38%
Tags
conferences
-
Rhea-AI Summary
Gracell Biotechnologies Inc. plans to release unaudited financial results for Q3 2023 and provide an update on recent developments on November 13, 2023. The company is a global clinical-stage biopharmaceutical company focused on developing cell therapies for cancer and autoimmune diseases. A live audio webcast and conference call will be held at 8:00 AM Eastern Time. Conference call and webcast details can be found on the company's website. A replay of the webcast will be available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
conferences earnings
-
Rhea-AI Summary
Gracell Biotechnologies presents updated results for GC012F at International Myeloma Society Annual Meeting. 100% of patients achieved MRD- sCR. Overall response rate and safety profile were favorable.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.39%
Tags
Rhea-AI Summary
Gracell Biotechnologies announces dosing of first patient in Phase 1b/2 clinical trial for GC012F in relapsed or refractory multiple myeloma (RRMM)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.39%
Tags
-
Rhea-AI Summary
Gracell Biotechnologies Founder, Chairman, and CEO, Dr. William Cao, has been named to the PharmaVoice 100, recognizing inspiring leaders in the life-sciences industry. Dr. Cao's leadership has led to the development of a pipeline of CAR-T therapies, including the lead candidate GC012F, which has shown promising results in trials for multiple myeloma and non-Hodgkin's lymphoma. Gracell is also initiating trials for the treatment of refractory systemic lupus erythematosus. The company's FasTCAR next-day manufacturing platform was recognized for innovation in the industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.88%
Tags
none
-
Rhea-AI Summary
Gracell Biotechnologies Inc. (NASDAQ: GRCL) announces participation in upcoming investor conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
conferences
Rhea-AI Summary
Gracell Biotechnologies to present updated results from Phase 1 trial on GC012F at IMS Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
conferences clinical trial
Gracell Biotechnologies Inc

Nasdaq:GRCL

GRCL Rankings

GRCL Stock Data

989.87M
165.04M
16.39%
63.11%
1.23%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
China
Suzhou

About GRCL

gracell biotechnologies inc. is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. leveraging its pioneering fastcar and truucar technology platforms, gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional car-t therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective car-t therapies for solid tumors.